In vivo CD8+ TCRISPR,Fli1

Zeyu Chen1, Eri Arai2, Omar Khan3

  • 1Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA.

Cell
|February 26, 2021
PubMed
まとめ

Fli1を削除すると,がんの免疫療法に不可欠なT細胞エフェクター機能が強化されます. この遺伝子改変はT細胞の分化を最適化することで 感染症や腫瘍に対する 防御的な免疫力を高めます